ChemoCentryx to Participate in Two Upcoming Investor Conferences
January 06 2021 - 08:30AM
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J.
Schall, Ph.D., President and Chief Executive Officer, will present
at two upcoming investor conferences and participate in a panel
discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.:
- 39th Annual J.P. Morgan Healthcare
ConferenceWednesday, January 13 at 11:40 a.m. Eastern
Time
- H.C. Wainwright Virtual BioConnect
ConferenceOn-demand presentation available beginning
Monday, January 11 at 6:00 a.m. Eastern Time
- Clinical Trial
Panel Discussion at the
H.C. Wainwright Virtual BioConnect ConferenceMonday,
January 11 at 12:00 p.m. Eastern Time
Live audio webcasts of the J.P. Morgan presentation and H.C.
Wainwright Clinical Trials Panel and on-demand presentation can be
accessed through the Investors section of the Company's website at
www.ChemoCentryx.com. Replays of both the J.P. Morgan and H.C.
Wainwright presentations will be available on the Company's website
for two weeks following the respective presentation dates.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications for inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and
chemoattractant systems to discover, develop and commercialize
orally administered therapies. ChemoCentryx’s lead drug candidate,
avacopan (CCX168), successfully completed a pivotal Phase III trial
in ANCA-associated vasculitis and a New Drug Application is under
review by the U.S. Food and Drug Administration, along with a
Marketing Authorization Application by the European Medicines
Agency. Avacopan is also in late-stage clinical development for the
treatment of Hidradenitis Suppurativa and C3 glomerulopathy
(C3G).
ChemoCentryx also has early-stage drug candidates that
target chemoattractant receptors in other inflammatory and
autoimmune diseases and in cancer.
Contacts:
Susan M. KanayaExecutive Vice President,Chief
Financial and Administrative Officerinvestor@chemocentryx.com
Media: Stephanie Tomei408.234.1279media@chemocentryx.com
Investors:Lee Roth, Burns McClellan212.213.0006
lroth@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Feb 2024 to Mar 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2023 to Mar 2024